Aeon Biopharma, INC. (AEON) — DEF 14A Filings

All DEF 14A filings from Aeon Biopharma, INC.. Browse 4 Proxy Statement reports with AI-powered summaries and risk analysis.

DEF 14A Filings (4)

AEON Biopharma Seeks Shareholder Nod for Critical Financing, Equity Deals — Dec 29, 2025 Risk: high
AEON Biopharma, Inc. is holding a Special Meeting on January 21, 2026, to approve critical financing and equity proposals aimed at funding the development and p
AEON Biopharma Files 2024 Proxy Statement — Apr 29, 2025 Risk: low
AEON Biopharma, Inc. filed its definitive proxy statement for the fiscal year ending December 31, 2024. The filing, dated April 29, 2025, outlines the company's
AEON Biopharma Files Definitive Proxy Statement — Jan 23, 2025 Risk: low
AEON Biopharma, Inc. filed its definitive proxy statement on January 23, 2025, for its annual meeting on February 24, 2025. The company, formerly known as Prive
AEON Biopharma, Inc. Announces 2024 Annual Meeting of Stockholders — Apr 29, 2024 Risk: low
AEON Biopharma, Inc. (AEON) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. AEON Biopharma, Inc. will hold its 2024 Annual Meeting of Stockhol

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX